Notably, antibody‐mediated neutralization of TDE‐associated TGF‐β1 and/or IL‐10 inhibited Treg induction and expansion during tumor therapy.119 A therapeutic strategy that consists of both a conventional therapy and a TDE‐targeted therapy may therefore represent a promising approach to induce more effective tumor‐directed immune responses, and thereby limit the potential for tumor recurrence and metastasis. The gene discussed is IL10; the disease is neoplasm.